241 related articles for article (PubMed ID: 30068244)
41. Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.
Pasic I; Da'na W; Lam W; Law A; Lipton JH; Viswabandya A; Kim DD; Thyagu S; Messner HA; Michelis FV
Eur J Haematol; 2019 Apr; 102(4):368-374. PubMed ID: 30706524
[TBL] [Abstract][Full Text] [Related]
42. Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML.
Duléry R; Nibourel O; Gauthier J; Elsermans V; Behal H; Coiteux V; Magro L; Renneville A; Marceau A; Boyer T; Quesnel B; Preudhomme C; Duhamel A; Yakoub-Agha I
Bone Marrow Transplant; 2017 Apr; 52(4):539-543. PubMed ID: 28067876
[TBL] [Abstract][Full Text] [Related]
43. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.
Bacher U; Badbaran A; Fehse B; Zabelina T; Zander AR; Kröger N
Exp Hematol; 2009 Jan; 37(1):135-42. PubMed ID: 19100523
[TBL] [Abstract][Full Text] [Related]
44. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
45. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation.
Zhao X; Wang Z; Ruan G; Liu Y; Wang Y; Zhang X; Xu L; Huang X; Chang Y
Ann Hematol; 2018 Jun; 97(6):967-975. PubMed ID: 29423758
[TBL] [Abstract][Full Text] [Related]
46. The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission.
Zheng C; Zhu X; Tang B; Zhang L; Geng L; Liu H; Sun Z
Leuk Lymphoma; 2016; 57(6):1398-405. PubMed ID: 26690538
[TBL] [Abstract][Full Text] [Related]
47. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia.
Shah MV; Jorgensen JL; Saliba RM; Wang SA; Alousi AM; Andersson BS; Bashir Q; Ciurea SO; Kebriaei P; Marin D; Patel KP; Popat UR; Rezvani K; Rondon G; Shpall EJ; Champlin RE; Oran B
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1514-1520. PubMed ID: 29448058
[TBL] [Abstract][Full Text] [Related]
48. Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study.
Frairia C; Aydin S; Audisio E; Riera L; Aliberti S; Allione B; Busca A; D'Ardia S; Dellacasa CM; Demurtas A; Evangelista A; Ciccone G; Francia di Celle P; Nicolino B; Stacchini A; Marmont F; Vitolo U
Leuk Res; 2017 Oct; 61():10-17. PubMed ID: 28846953
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
Kim HJ; Kim Y; Kang D; Kim HS; Lee JM; Kim M; Cho BS
Blood Cancer J; 2021 Jun; 11(6):109. PubMed ID: 34088902
[TBL] [Abstract][Full Text] [Related]
50. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
51. Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies.
Gaut D; Mead M
Leuk Lymphoma; 2021 Jan; 62(1):8-31. PubMed ID: 33138674
[TBL] [Abstract][Full Text] [Related]
52. Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing.
Ahn JS; Kim T; Jung SH; Ahn SY; Jung SY; Song GY; Kim M; Yang DH; Lee JJ; Choi S; Lee JY; Park SK; Moon JH; Lee HY; Kim KH; Cai Y; Yi SY; Novitzky-Basso I; Zhang Z; Kim HJ; Kim DDH
Bone Marrow Transplant; 2021 May; 56(5):1159-1170. PubMed ID: 33279940
[TBL] [Abstract][Full Text] [Related]
53. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
54. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Jongen-Lavrencic M; Grob T; Hanekamp D; Kavelaars FG; Al Hinai A; Zeilemaker A; Erpelinck-Verschueren CAJ; Gradowska PL; Meijer R; Cloos J; Biemond BJ; Graux C; van Marwijk Kooy M; Manz MG; Pabst T; Passweg JR; Havelange V; Ossenkoppele GJ; Sanders MA; Schuurhuis GJ; Löwenberg B; Valk PJM
N Engl J Med; 2018 Mar; 378(13):1189-1199. PubMed ID: 29601269
[TBL] [Abstract][Full Text] [Related]
55. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
56. Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing.
Ritterhouse LL; Parilla M; Zhen CJ; Wurst MN; Puranik R; Henderson CM; Joudeh NZ; Hartley MJ; Haridas R; Wanjari P; Furtado LV; Kadri S; Segal JP
Mol Diagn Ther; 2019 Dec; 23(6):791-802. PubMed ID: 31673932
[TBL] [Abstract][Full Text] [Related]
57. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
58. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.
Chang YJ; Wang Y; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ
J Hematol Oncol; 2017 Jul; 10(1):134. PubMed ID: 28676064
[TBL] [Abstract][Full Text] [Related]
59. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
Rashidi A; Linden MA; DeFor TE; Warlick E; Bejanyan N; Yohe S; Weisdorf DJ; Ustun C
Am J Hematol; 2017 Oct; 92(10):1032-1036. PubMed ID: 28646534
[TBL] [Abstract][Full Text] [Related]
60. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
